REGISTERED NUMBER: 16286973 (England and Wales)

Financial Statements

for the Period

3 March 2025 to 31 March 2026

for

Tangible Biosciences Ltd

Page

Company Information

1

Balance Sheet

2

Notes to the Financial Statements

3

DIRECTORS:

E K P Chow

N H G Lang

X J A Simpson

T Haines

Mrs M Y F Haines

SECRETARY:

P F G Binney

REGISTERED OFFICE:

Springfield House

Springfield Road

Horsham

West Sussex

RH12 2RG

REGISTERED NUMBER:

16286973 (England and Wales)

AUDITORS:

Aspen Waite

Chartered Certified Accountants

Rubis House

15 Friarn Street

Bridgwater

Somerset

TA6 3LH

FIXED ASSETS

Intangible assets

4

5,133,735

CURRENT ASSETS

Debtors

5

1,853,971

Cash at bank

18,779

1,872,750

CREDITORS

Amounts falling due within one year

6

294,416

NET CURRENT ASSETS

1,578,334

TOTAL ASSETS LESS CURRENT LIABILITIES

6,712,069

CAPITAL AND RESERVES

Called up share capital

7

6,716,418

Retained earnings

(4,349

)

6,712,069

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 12 June 2026 and were signed on its behalf by:

E K P Chow - Director

1.	STATUTORY INFORMATION

Tangible Biosciences Ltd is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The presentation currency of the financial statements is the Pound Sterling (£).

2.	ACCOUNTING POLICIES

Basis of preparing the financial statements

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Intangible assets

Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Development costs are being amortised evenly over their estimated useful life of nil years.

Taxation

Taxation for the period comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the period end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

3.	EMPLOYEES AND DIRECTORS

The average number of employees during the period was 1 .

4.	INTANGIBLE FIXED ASSETS

Development

costs

£

COST

Additions

5,133,735

At 31 March 2026

5,133,735

NET BOOK VALUE

At 31 March 2026

5,133,735

5.

DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

£

VAT

94,240

Called up share capital not paid

1,759,731

1,853,971

6.

CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

£

Trade creditors

209,586

Amounts owed to associates

80,330

Other creditors

4,500

294,416

7.	CALLED UP SHARE CAPITAL

Deferred Shares - USD $5,000,000 = £3,171,641.79

Deferred Shares (Option Shares) - £559,701.49

Investment Shares (Series A) - Timothy Haines - £746,268.66

Investment Shares (Series A) - CRC - £2,238,805.97

£6,716,418

Exchange rate USD$1.34 to GBP£1

8.	DISCLOSURE UNDER SECTION 444(5B) OF THE COMPANIES ACT 2006

The Report of the Auditors was unqualified.

Paul David Waite (Senior Statutory Auditor)

for and on behalf of Aspen Waite

9.	ULTIMATE CONTROLLING PARTY

The ultimate controlling party is CellResearch Corporation Pte.Ltd.

The address and principal place of business of the ultimate holding company is located at 137 Market Street, #08-02 Grace Global Raffles Building, Singapore 048943